Evidence map›Paper›PMID 37085258›Full record

ArticleKidney international2023

The case for treatment of monogenic SRNS with calcineurin inhibitors.

Brandon M Lane, Rasheed A Gbadegesin

Open access · greenAbstract readComment
In one paragraph

Article in Kidney international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Brandon M LaneDepartment of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA.
Rasheed A GbadegesinDepartment of Pediatrics, Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA; Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA. Electronic address: rasheed.gbadegesin@duke.edu.
Duke University · US

Funding

REGULATORS OF CALCINEURIN PATHWAYS AS DIAGNOSTIC AND THERAPEUTIC TARGETS FOR NEPHROTIC SYNDROMER01DK134347 · NIDDK · DUKE UNIVERSITY · PI Rasheed Adebayo Gbadegesin · 2023 to 2026
$2.6M
GENETIC BASIS OF CORTICOSTEROID RESPONSE IN CHILDHOOD NEPHROTIC SYNDROMER21HD104176 · NICHD · DUKE UNIVERSITY · PI GBADEGESIN, RASHEED ADEBAYO · 2021 to 2022
$443k
NICHD NIH HHS R21 HD104176NIDDK NIH HHS R01 DK134347
6 · The paper itself

Abstract

Currently, no evidence-based guidelines exist for treatment of children with monogenic steroid-resistant nephrotic syndrome. A retrospective study on 141 patients from Malakasioti et al. revealed that 27.6% responded to calcineurin inhibitor (CNI) treatment, and 75% of responders maintained stable kidney function. Virtually all CNI nonresponders developed progressive loss of kidney function. This study emphasized roles for CNIs in patients with monogenic steroid-resistant nephrotic syndrome, and the need for future studies to identify CNI response biomarkers.

Indexed as

Calcineurin InhibitorsNephrotic SyndromeBiomarkersChildHumansImmunosuppressive AgentsRetrospective StudiesBiomarkersCalcineurin InhibitorsImmunosuppressive Agents

Identifiers

PMID37085258
PMCPMC10434727
OpenAlexW4366437291

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.